• Sign the informed consent form voluntarily and follow the protocol requirements;

• Any gender;

• Age: ≥18 years old;

• Expected survival time for 3 months or more;

• Patients with locally advanced or metastatic non-small cell lung cancer or nasopharyngeal carcinoma confirmed by histopathology and/or cytology;

• Subjects were able to provide 6-10 slides of archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 2 years;

• At least one measurable lesion meeting the RECIST v1.1 definition was required;

• ECOG 0 or 1;

• The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

⁃ No serious cardiac dysfunction, left ventricular ejection fraction 50% or higher;

⁃ screening period not allowed within 14 days before a blood transfusion, are not allowed to use any cell growth factor, and/or liters of platelet medicine, organ function level must conform to the requirements;

⁃ Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN;

⁃ The urine protein + 2 or 1000 mg / 24 h or less or less;

⁃ For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.